27 recruiting, 9 active not recruiting, 4 completed, 3 not yet recruiting. 31 Phase 2, 14 Phase 1, 5 Phase 3.
Follow Mosunetuzumab: new trials by email Literature Review of Mosunetuzumab trials Research Report on Mosunetuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER) Pirtobrutinib, Mosunetuzumab - Waldenstrom Macroglobulinemia | Phase 2 | Not yet recruiting | University of Utah | 25 | 2026-11-01 | 2026-09-24 |
| Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Nodal Marginal Zone Lymphoma | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 138 | 2026-10-03 | 2026-10-13 |
| Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD Mosunetuzumab - Lymphocytic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2026-07-09 | 2026-08-12 |
| Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma Polatuzumab Vedotin, Mosunetuzumab, Cyclophosphamide - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Medical College of Wisconsin | 31 | 2026-06-01 | 2026-08-25 |
| A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis Mosunetuzumab - Lupus, Systemic Lupus Erythematosus | Phase 2 | Recruiting | Hoffmann-La Roche | 30 | 2026-05-25 | 2026-10-19 |
| Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma Mosunetuzumab, Zeprumetostat - Follicular Lymphoma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 80 | 2026-04-10 | 2026-06-09 |
| Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP). Mosunetuzumab - Relapsed/Refractory Follicular Lymphoma | Recruiting | Andrés José Maria Ferreri | 25 | 2025-12-01 | 2026-02-03 | |
| Mosunetuzumab for CLL MRD Clearance Mosunetuzumab, Ibrutinib, Acalabrutinib - Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Inhye Ahn | 40 | 2025-11-24 | 2025-12-15 |
| Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial Pirtobrutinib, Mosunetuzumab, Biospecimen Collection - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 2 | Recruiting | University of Washington | 22 | 2025-11-17 | 2026-06-04 |
| A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP Mosunetuzumab, ClonoSEQ - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Danielle Wallace | 40 | 2025-09-04 | 2025-10-20 |
| A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL Mosunetuzumab, Tislelizumab - Relapsed/Refractory Follicular Lymphoma | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 22 | 2025-07-01 | 2025-06-22 |
| A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma Mosunetuzumab, Zanubrutinib - Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 36 | 2024-12-11 | 2026-10-05 |
| A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies Tacabrutideg, Sonrotoclax, Zanubrutinib - B-cell Malignancy, Relapsed Cancer | Phase 1 / Phase 2 | Recruiting | BeOne Medicines | 80 | 2024-11-27 | 2026-09-11 |
| Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma Mosunetuzumab - Extranodal Marginal Zone Lymphoma | Phase 2 | Recruiting | Izidore Lossos, MD | 35 | 2024-11-19 | 2026-10-15 |
| Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma Biospecimen Collection, Computed Tomography, Mosunetuzumab - Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features | Phase 3 | Recruiting | National Cancer Institute (NCI) | 600 | 2024-10-23 | 2026-10-29 |
| Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 41 | 2024-09-09 | 2026-09-22 |
| Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma | Phase 2 | Recruiting | University of Washington | 20 | 2024-08-29 | 2026-08-27 |
| Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | OHSU Knight Cancer Institute | 40 | 2024-06-13 | 2026-07-07 |
| Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 Mosunetuzumab, Lenalidomide, Rituximab - Follicular Lymphoma | Phase 3 | Active not recruiting | The Lymphoma Academic Research Organisation | 790 | 2024-06-07 | 2026-09-25 |
| Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Lenalidomide - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-05-20 | 2026-10-26 |
Showing 20 of 45. Sign in to see all of them.
Lymphoma, Follicular (15) · Lymphoma, B-Cell (8) · Lymphoma, Large B-Cell, Diffuse (7) · Lymphoma (4) · Lymphoma, B-Cell, Marginal Zone (4) · Lymphoma, Non-Hodgkin (4) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lupus Erythematosus, Systemic (2) · Recurrence (2) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia (1) · Leukemia, Lymphoid (1)
Hoffmann-La Roche (7) · M.D. Anderson Cancer Center (4) · National Cancer Institute (NCI) (3) · University of Washington (3) · Washington University School of Medicine (3) · City of Hope Medical Center (2) · SWOG Cancer Research Network (2) · The Lymphoma Academic Research Organisation (2) · ADC Therapeutics S.A. (1) · Abramson Cancer Center at Penn Medicine (1) · Andrés José Maria Ferreri (1) · BeOne Medicines (1) · Bristol-Myers Squibb (1) · Brown University (1) · Danielle Wallace (1)
United States (37) · Italy (8) · China (6) · France (6) · Germany (6) · Spain (6) · Poland (5) · South Korea (5) · Australia (4) · Brazil (4) · United Kingdom (4) · Belgium (3) · Japan (3) · Turkey (Türkiye) (3) · Argentina (2)
Adam J Olszewski, MD (1) · Ajay Gopal (1) · Armin Ghobadi, M.D. (1) · Boyu Hu (1) · Brian T Hess (1) · Dai Chihara, MD,PHD (1) · David A Russler-Germain, M.D., Ph.D. (1) · David Russler-Germain, M.D., Ph.D. (1) · Inhye Ahn, MD (1)
PMID 42309556, PMID 37581593, PMID 39319495, PMID 39908481, PMID 40550489, PMID 41037766, PMID 41670385, PMID 42283231, PMID 42298056, PMID 42600120
U10CA180888 (3), P30CA033572 (2), 2018 (1), 2023 (1), UM1CA186691 (1), UM1CA186717 (1)